Pharmaceutical

EC approves Vertex’s Orkambi for cystic fibrosis in children

The EC approved extending the label for Vertex Pharmaceuticals’ Orkambi to treat cystic fibrosis in children aged one to two years.

Jul 5, 2023 - 20:00
EC approves Vertex’s Orkambi for cystic fibrosis in children
The EC approved extending the label for Vertex Pharmaceuticals’ Orkambi to treat cystic fibrosis in children aged one to two years.
Read the original article

Tags:

Previous Article

MHRA reveals new corporate plan to expedite drug regulatory journeys in UK

Next Article

FSD Pharma names Zeeshan Saeed as new CEO

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: A new HHS rule takes a far too narrow approach to health care data interoperability

Opinion: A new HHS rule takes a far too narrow approach...

Jan 18, 2024

STAT+: Moderna CEO made $398 million in 2022, but still pledges to give most to charity

STAT+: Moderna CEO made $398 million in 2022, but still...

Mar 19, 2023

STAT+: Drug companies and pharmacies reach $17.3 billion settlement over opioid crisis

STAT+: Drug companies and pharmacies reach $17.3 billio...

Jun 10, 2023